cinpanemab   Click here for help

GtoPdb Ligand ID: 13331

Synonyms: antibody 12F4 | BIIB-054 | BIIB054
Compound class: Antibody
Comment: Cinpanemab (BIIB054) is a monoclonal antibody that binds aggregated α-synuclein [3]. Specifically it binds to the N terminus of α-synuclein. It was designed to reduce the cell-to-cell spread of toxic α-synuclein aggregates in the brains of people with Parkinson's disease, as a disease-modifying therapeutic approach to slow the rate of neuronal damage and disease progression.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Biogen discontinued development of cinpanemab in 2021 due to lack of efficacy in clinical trial [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02459886 Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease Phase 1 Interventional Biogen
NCT03318523 Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease Phase 2 Interventional Biogen This study failed to meet its prespecified primary and secondary endpoints and was terminated early due to this lack of efficacy. 1-2